Myelomas
A Phase 3, Multicenter, Randomized, Open-Label Study of Etentamig Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (M22-574)
- Details
ClinicalTrials.gov ID:
NCT06158841
Diagnosis Type:
NA
USOR Number:
- Address
,
P: